메뉴 건너뛰기




Volumn 109, Issue 7, 2007, Pages 1365-1375

Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns

Author keywords

BCR ABL mutation; Clinical practice; CML; Dasatinib; Imatinib; Molecular monitoring; Survey

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

EID: 33947496833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22523     Document Type: Article
Times cited : (41)

References (28)
  • 1
    • 0345696854 scopus 로고    scopus 로고
    • Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group
    • Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
    • (1997) N Engl J Med , vol.337 , pp. 223-229
    • Guilhot, F.1    Chastang, C.2    Michallet, M.3
  • 2
    • 14644425319 scopus 로고    scopus 로고
    • Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    • Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183.
    • (2005) Nat Rev Cancer , vol.5 , pp. 172-183
    • Ren, R.1
  • 3
    • 33747154547 scopus 로고    scopus 로고
    • Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 4
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3
  • 5
    • 33947502075 scopus 로고    scopus 로고
    • Guilhot F, Larson R, O'Brien S, Druker B, on behalf of IRIS Study Group. Long-term benefits of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: the 5-year update from the IRIS study. Haematologica. 2006;91:170. Abstract 466.
    • Guilhot F, Larson R, O'Brien S, Druker B, on behalf of IRIS Study Group. Long-term benefits of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: the 5-year update from the IRIS study. Haematologica. 2006;91:170. Abstract 466.
  • 7
    • 33748791111 scopus 로고    scopus 로고
    • Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study [abstract]
    • 338s. Abstract 6506
    • Druker B, Guilhot F, O'Brien S, Larson R. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:338s. Abstract 6506.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Druker, B.1    Guilhot, F.2    O'Brien, S.3    Larson, R.4
  • 8
    • 33644544742 scopus 로고    scopus 로고
    • Chronic myeloid leukemia in 2006: A perspective
    • Mauro M, Deininger M. Chronic myeloid leukemia in 2006: a perspective. Hematologica. 2006;91:152-158.
    • (2006) Hematologica , vol.91 , pp. 152-158
    • Mauro, M.1    Deininger, M.2
  • 9
    • 30844433972 scopus 로고    scopus 로고
    • Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia
    • Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20:29-41.
    • (2006) Blood Rev , vol.20 , pp. 29-41
    • Hughes, T.1    Branford, S.2
  • 10
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
    • (2006) Blood , vol.108 , pp. 28-37
    • Hughes, T.1    Deininger, M.2    Hochhaus, A.3
  • 11
    • 20244365354 scopus 로고    scopus 로고
    • Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse
    • Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507-512.
    • (2005) Leukemia , vol.19 , pp. 507-512
    • Marin, D.1    Kaeda, J.2    Szydlo, R.3
  • 12
    • 9144253153 scopus 로고    scopus 로고
    • Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
    • Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17:2392-2400.
    • (2003) Leukemia , vol.17 , pp. 2392-2400
    • Muller, M.C.1    Gattermann, N.2    Lahaye, T.3
  • 13
    • 0141613844 scopus 로고    scopus 로고
    • Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
    • Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694.
    • (2003) Leukemia , vol.17 , pp. 1687-1694
    • Paschka, P.1    Muller, M.C.2    Merx, K.3
  • 14
    • 3242794241 scopus 로고    scopus 로고
    • Monitoring of minimal residual disease in chronic myeloid leukemia
    • Faderl S, Hochhaus A, Hughes T. Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:657-670,ix-x.
    • (2004) Hematol Oncol Clin North Am , vol.18
    • Faderl, S.1    Hochhaus, A.2    Hughes, T.3
  • 15
    • 33947495873 scopus 로고    scopus 로고
    • NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia version 1. Jenkintown, PA: NCCN;2006.
    • NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia version 1. Jenkintown, PA: NCCN;2006.
  • 17
    • 33746086705 scopus 로고    scopus 로고
    • Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era
    • Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant. 2006;12:795-807.
    • (2006) Biol Blood Marrow Transplant , vol.12 , pp. 795-807
    • Grigg, A.1    Hughes, T.2
  • 18
    • 33750057418 scopus 로고    scopus 로고
    • High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up [abstract]
    • 345s. Abstract 6535
    • Aoki E, Kantarjian H, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:345s. Abstract 6535.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Aoki, E.1    Kantarjian, H.2    O'Brien, S.3
  • 19
    • 33750082751 scopus 로고    scopus 로고
    • Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study
    • 344s. Abstract 6528
    • Coutre S, Martinelli G, Dombret H, et al. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 'START-L' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6528.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Coutre, S.1    Martinelli, G.2    Dombret, H.3
  • 20
    • 33750080209 scopus 로고    scopus 로고
    • Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' study
    • 339s. Abstract 6508
    • Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 'START-C' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:339s. Abstract 6508.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Hochhaus, A.1    Kantarjian, H.2    Baccarani, M.3
  • 21
    • 33750045494 scopus 로고    scopus 로고
    • Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study
    • 343s. Abstract 6526
    • Talpaz M, Apperley J, Kim D, et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:343s. Abstract 6526.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Talpaz, M.1    Apperley, J.2    Kim, D.3
  • 22
    • 33845739041 scopus 로고    scopus 로고
    • Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial [abstract]
    • 338s. Abstract 6507
    • Shah N, Rousselot P, Pasquini R, et al. Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:338s. Abstract 6507.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Shah, N.1    Rousselot, P.2    Pasquini, R.3
  • 23
    • 33947508210 scopus 로고    scopus 로고
    • Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study [abstract]
    • 344s. Abstract 6529
    • Cortes J, Kim D, Rosti G, et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 'START-B' study [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6529.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Cortes, J.1    Kim, D.2    Rosti, G.3
  • 24
    • 33750089041 scopus 로고    scopus 로고
    • A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)
    • 346s. Abstract 6536
    • Giles F, Larson R, Le Coutre P, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:346s. Abstract 6536.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Giles, F.1    Larson, R.2    Le Coutre, P.3
  • 25
    • 33947529573 scopus 로고    scopus 로고
    • A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]
    • 344s. Abstract 6531
    • Le Coutre P, Ottman O, Gattermann N, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6531.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Le Coutre, P.1    Ottman, O.2    Gattermann, N.3
  • 26
    • 33750060345 scopus 로고    scopus 로고
    • A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]
    • 345s. Abstract 6534
    • Kantarjian H, Gattermann N, O'Brien S, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:345s. Abstract 6534.
    • (2006) J Clin Oncol (ASCO Annual Meeting Proc) , vol.24
    • Kantarjian, H.1    Gattermann, N.2    O'Brien, S.3
  • 27
    • 13844307432 scopus 로고    scopus 로고
    • on behalf of the IRIS (International Randomized IFN vs. STI571) study group. Probability and impact of obtaining a cytogenetic response to Imatinib as initial therapy for chronic myeloid leukemia in chronic phase
    • Abstract 634
    • Druker B, Gathmann I, Bolton A, Larson R, on behalf of the IRIS (International Randomized IFN vs. STI571) study group. Probability and impact of obtaining a cytogenetic response to Imatinib as initial therapy for chronic myeloid leukemia in chronic phase. Blood. 2003;102:182a. Abstract 634.
    • (2003) Blood , vol.102
    • Druker, B.1    Gathmann, I.2    Bolton, A.3    Larson, R.4
  • 28
    • 10744229080 scopus 로고    scopus 로고
    • Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia
    • Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
    • (2003) N Engl J Med , vol.349 , pp. 1423-1432
    • Hughes, T.P.1    Kaeda, J.2    Branford, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.